Doubling of SCr4 · people with diabetes and kidney disease
Angiotensin receptor blocker (ARB) showed no clear difference in doubling of SCr4 compared with another ARB (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin receptor blocker (ARB) showed no clear difference in fatal or nonfatal stroke6 compared with another ARB (low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
Angiotensin receptor blocker (ARB) showed no clear difference in fatal or nonfatal myocardial infarction7 compared with another ARB (low certainty).
1 finding from 1 review
Micro‐ to macroalbuminuria · people with diabetes and kidney disease
Angiotensin receptor blocker (ARB) showed no clear difference in micro‐ to macroalbuminuria 8 compared with another ARB (low certainty).
1 finding from 1 review
Micro‐ to normoalbuminuria9 · people with diabetes and kidney disease
Angiotensin receptor blocker (ARB) showed no clear difference in micro‐ to normoalbuminuria9 compared with another ARB (low certainty).
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).
1 finding from 1 review
All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Quality of life (MLHFQ): from 0 to 105 · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
Residual kidney function (24 months) · patients receiving PD
4 findings from 1 review
no estimate extracted
1 study · 44 participants
Moderate
no estimate extracted
1 study · 44 participants
Moderate
no estimate extracted
3 studies · 110 participants
Moderate
Show 1 more finding
Diastolic blood pressure · patients receiving PD
1 finding from 1 review
Serum potassium · patients receiving PD
1 finding from 1 review
Peritonitis · patients receiving PD
Angiotensin receptor blockers (ARBs) showed no clear difference in adverse events (episodes of peritonitis) compared with conventional therapy (low certainty).
1 finding from 1 review
Residual kidney function (12 months) · patients receiving PD
1 finding from 1 review
Urinary protein excretion · patients receiving PD
1 finding from 1 review
Kt/V · patients receiving PD
1 finding from 1 review
Creatinine clearance · patients receiving PD
1 finding from 1 review
Systolic blood pressure · patients receiving PD
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors showed no clear difference in all‐cause death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review